Morgan Stanley Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $69
Biohaven Ltd. (BHVN) Receives a Buy From Morgan Stanley
A Quick Look at Today's Ratings for Biohaven(BHVN.US), With a Forecast Between $59 to $76
Promising Therapeutic Advancements Propel Biohaven Ltd. to Buy Rating: Analyst Douglas Tsao Highlights Key Developments in SCA, SMA, and Migraine Treatments
Biohaven Is Maintained at Outperform by RBC Capital
RBC Capital Maintains Biohaven(BHVN.US) With Buy Rating, Cuts Target Price to $66